Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · see citing works

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data

Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455 · see citing works

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · see citing works

Mutations of the BRAF gene in human cancer

Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · see citing works

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157 · see citing works

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · see citing works

Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation

Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · see citing works

Cancer Cell Cycles

Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379 · see citing works

The senescence-associated secretory phenotype: the dark side of tumor suppression

Coppé, J.-P., Desprez, P.-Y., Krtolica, A., & Campisi, J. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-121808-102144 · Cited by 5,206 · see citing works

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · see citing works

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910836 · Cited by 3,723 · see citing works

A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.

Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650 · see citing works

Targeting RAS signalling pathways in cancer therapy

Downward, J. (2003) · Nature reviews. Cancer · doi:10.1038/nrc969 · Cited by 3,262 · see citing works

Genomic classification of cutaneous melanoma

Akbani, R., Akdemir, K. C., Aksoy, B. A., Albert, M., Ally, A., Amin, S. B., Arachchi, H., Arora, A., Auman, J. T., Ayala, B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.044 · Cited by 3,151 · see citing works

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088 · see citing works

CTLA-4 Control over Foxp3 ⁺ Regulatory T Cell Function

Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956 · see citing works

Cellular senescence: from physiology to pathology

Muñoz-Espín, D., & Serrano, M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3823 · Cited by 2,818 · see citing works

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810 · see citing works

Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF

Wan, P., Garnett, M. J., Roe, S. M., Lee, S., Niculescu‐Duvaz, D., Good, V. M., Cancer Genome Project, Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,800 · see citing works

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781 · see citing works

Distinct Sets of Genetic Alterations in Melanoma

Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050092 · Cited by 2,747 · see citing works

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis

Wang, D. Y., Salem, J.-E., Cohen, J. V., Chandra, S., Menzer, C., Ye, F., Zhao, S., Das, S., Beckermann, K. E., Ha, L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3923 · Cited by 2,674 · see citing works

The regulation of E2F by pRB-family proteins.

Dyson, N. (1998) · Genes &amp; Development · doi:10.1101/gad.12.15.2245 · Cited by 2,317 · see citing works

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,149 · see citing works

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

Poulikakos, P. I., Zhang, C., Bollag, G. E., Shokat, K. M., & Rosen, N. X. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,818 · see citing works

Addiction to Oncogenes--the Achilles Heal of Cancer

Weinstein, I. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,753 · see citing works

Clonal replacement of tumor-specific T cells following PD-1 blockade

Yost, K. E., Satpathy, A. T., Wells, D. K., Qi, Y., Wang, C., Kageyama, R., McNamara, K. L., Granja, J. M., Sarin, K. Y., Brown, R. A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0522-3 · Cited by 1,534 · see citing works

CDK4/6 inhibition triggers anti-tumour immunity

Goel, S., DeCristo, M. J., Watt, A. C., BrinJones, H., Sceneay, J., Li, B. B., Khan, N., Ubellacker, J. M., Xie, S., Metzger-Filho, O., et al. (2017) · Nature · doi:10.1038/nature23465 · Cited by 1,513 · see citing works

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

Heidorn, S. J., Milagre, C. S., Whittaker, S. R., Nourry, A., Niculescu‐Duvaz, I., Dhomen, N. S., Hussain, J., Reis-Filho, J. S., Springer, C. J., Pritchard, C. A., et al. (2010) · Cell · doi:10.1016/j.cell.2009.12.040 · Cited by 1,468 · see citing works

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398 · see citing works

Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma

Robert, C., Grob, J. J., Stroyakovskiy, D., Karaszewska, B., Hauschild, A., Levchenko, E., Chiarion Sileni, V., Schachter, J., Garbe, C., Bondarenko, I., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1904059 · Cited by 1,389 · see citing works

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711741105 · Cited by 1,346 · see citing works

Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-63198 · Cited by 1,330 · see citing works

Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4

(1993) · Genes &amp; Development · doi:10.1101/gad.7.3.331 · Cited by 1,264 · see citing works

CTLA-4: a moving target in immunotherapy

Rowshanravan, B., Halliday, N., & Sansom, D. M. (2018) · Blood · doi:10.1182/blood-2017-06-741033 · Cited by 1,233 · see citing works

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

Schachter, J., Ribas, A., Long, G. V., Arance, A. M., Grob, J., Mortier, L., DAUD, A. I., Carlino, M. S., McNeil, C. M., Lotem, M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31601-x · Cited by 1,226 · see citing works

RB and cell cycle progression

Giacinti, C., & Giordano, A. (2006) · Oncogene · doi:10.1038/sj.onc.1209615 · Cited by 1,218 · see citing works

Cyclin D1 Expression Is Regulated Positively by the p42/p44 and Negatively by the p38/HOG Pathway

Lavoie, J. N., L’Allemain, G., Brunet, A., Müller, R., & Pouysségur, J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.34.20608 · Cited by 1,210 · see citing works

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

Robert, C., Ribas, A., Schachter, J., Arance, A., Grob, J.-J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C. M., Lotem, M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30388-2 · Cited by 1,159 · see citing works

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

Ribas, A., Hamid, O., Daud, A., Hodi, F. S., Wolchok, J. D., Kefford, R., Joshua, A. M., Patnaik, A., Hwu, W.-J., Weber, J. S., et al. (2016) · JAMA · doi:10.1001/jama.2016.4059 · Cited by 1,069 · see citing works

Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation

van Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020 · see citing works

Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance

Zhang, J., Bu, X., Wang, H., Zhu, Y., Geng, Y., Nihira, N. T., Tan, Y., Ci, Y., Wu, F., Dai, X., et al. (2018) · Nature · doi:10.1038/nature25015 · Cited by 1,013 · see citing works

Functional interactions of the retinoblastoma protein with mammalian D-type cyclins

Ewen, M. E., Sluss, H. K., Sherr, C. J., Matsushime, H., Kato, J.-Y., & Livingston, D. M. (1993) · Cell · doi:10.1016/0092-8674(93)90136-e · Cited by 1,010 · see citing works

Cellular mechanisms of tumour suppression by the retinoblastoma gene

Burkhart, D. L., & Sage, J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2399 · Cited by 974 · see citing works

How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer?

Mebratu, Y. A., & Tesfaigzi, Y. (2009) · Cell Cycle · doi:10.4161/cc.8.8.8147 · Cited by 959 · see citing works

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma

Frederick, D. T., Piris, A., Cogdill, A. P., Cooper, Z. A., Lezcano, C., Ferrone, C. R., Mitra, D., Boni, A., Newton, L. P., Liu, C., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1630 · Cited by 944 · see citing works

Targeting CDK4 and CDK6: From Discovery to Therapy

Sherr, C. J., Beach, D., & Shapiro, G. I. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0894 · Cited by 936 · see citing works

Identification and properties of an atypical catalytic subunit (p34PSK-J3/Cdk4) for mammalian D type G1 cyclins

Matsushime, H., Ewen, M. E., Strom, D. K., Kato, J.-Y., Hanks, S. K., Roussel, M. F., & Sherr, C. J. (1992) · Cell · doi:10.1016/0092-8674(92)90360-o · Cited by 897 · see citing works

Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi

Gandini, S., Sera, F., Cattaruzza, M. S., Pasquini, P., ABENI, D. D., Boyle, P., & Melchi, C. F. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.10.015 · Cited by 838 · see citing works

Guilty as charged

Garnett, M. J., & Marais, R. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.022 · Cited by 799 · see citing works

Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6

Malumbres, M., Sotillo, R., Santamarı́a, D., Galán, J., Cerezo, A., Ortega, S., Dubus, P., & Barbacid, M. (2004) · Cell · doi:10.1016/j.cell.2004.08.002 · Cited by 793 · see citing works

Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade

House, I. G., Savas, P., Lai, J., Chen, A. X. Y., Oliver, A. J., Teo, Z. L., Todd, K. L., Henderson, M. A., Giuffrida, L., Petley, E. V., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1868 · Cited by 790 · see citing works

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation

Deng, J., Wang, E. S., Jenkins, R. W., Li, S., Dries, R., Yates, K., Chhabra, S., Huang, W., Liu, H., Aref, A. R., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0915 · Cited by 770 · see citing works

Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer

(1996) · Advances in cancer research · doi:10.1016/s0065-230x(08)60352-8 · Cited by 752 · see citing works

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.

Boni, A., Cogdill, A. P., Dang, P., Udayakumar, D., Njauw, C.-N. J., Sloss, C. M., Ferrone, C. R., Flaherty, K. T., Lawrence, D. P., Fisher, D. E., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0118 · Cited by 742 · see citing works

Intratumoral activity of the cxcr3 chemokine system is required for the efficacy of anti-PD-1 therapy

Chow, M. T., Ozga, A. J., Servis, R. L., Frederick, D. T., Lo, J. A., Fisher, D. E., Freeman, G. J., Boland, G. M., & Luster, A. D. (2019) · Immunity · doi:10.1016/j.immuni.2019.04.010 · Cited by 716 · see citing works

Hepatotoxicity with Combination of Vemurafenib and Ipilimumab

Ribas, A., Hodi, F. S., Callahan, M. K., Konto, C., & Wolchok, J. D. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1302338 · Cited by 713 · see citing works

MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade.

Ebert, P. J. R., Cheung, J., Yang, Y., McNamara, E., Hong, R., Moskalenko, M., Gould, S. E., Maecker, H., Irving, B. A., Kim, J. M., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.024 · Cited by 713 · see citing works

The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells

Sumimoto, H., Imabayashi, F., Iwata, T., & Kawakami, Y. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051848 · Cited by 700 · see citing works

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

Gutzmer, R., Stroyakovskiy, D., Gogas, H., Robert, C., Lewis, K., Protsenko, S., Pereira, R. P., Eigentler, T., Rutkowski, P., Demidov, L., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30934-x · Cited by 663 · see citing works

Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma

Wilmott, J. S., Long, G. V., Howle, J. R., Haydu, L. E., Sharma, R. N., Thompson, J. F., Kefford, R. F., Hersey, P., & Scolyer, R. A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2479 · Cited by 651 · see citing works

Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma

Hu‐Lieskovan, S., Mok, S., Moreno, B. H., Tsoi, J., Robert, L., Goedert, L., Pinheiro, E. M., Koya, R. C., Graeber, T. G., Comı́n-Anduix, B., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4691 · Cited by 565 · see citing works

Malignant Melanoma in the 21st Century, Part 1: Epidemiology, Risk Factors, Screening, Prevention, and Diagnosis

Markovic, S. N., Erickson, L. A., Rao, R. D., McWilliams, R. R., Kottschade, L. A., Creagan, E. T., Weenig, R. H., Hand, J. L., Pittelkow, M. R., Pockaj, B. A., et al. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.3.364 · Cited by 503 · see citing works

Assembly of cyclin D-dependent kinase and titration of p27 ^Kip1 regulated by mitogen-activated protein kinase kinase (MEK1)

Cheng, M., Sexl, V., Sherr, C. J., & Roussel, M. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.3.1091 · Cited by 496 · see citing works

The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition

Jiang, X., Zhou, J., Giobbie-Hurder, A., Wargo, J., & Hodi, F. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2731 · Cited by 485 · see citing works

BRAF/NRAS Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma

Colombino, M., Capone, M., Lissia, A., Cossu, A., Rubino, C., GIORGI, V. D., Massi, D., Fonsatti, E., Staibano, S., Nappi, O., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.2452 · Cited by 471 · see citing works

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade

Schaer, D. A., Beckmann, R. P., Dempsey, J. A., Huber, L., Forest, A., Amaladas, N., Li, Y., Wang, Y. C., Rasmussen, E. R., Chin, D., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.02.053 · Cited by 469 · see citing works

BRAFV600E: Implications for Carcinogenesis and Molecular Therapy

Dorris, E., O’Leary, J. J., & Sheils, O. M. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0799 · Cited by 460 · see citing works

Mutant BRAF and MEK inhibitors regulate the tumor immune microenvironment via pyroptosis

Erkes, D. A., Cai, W., Sanchez, I. M., Purwin, T. J., Rogers, C., Field, C. O., Berger, A. C., Hartsough, E. J., Rodeck, U., Alnemri, E. S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0672 · Cited by 459 · see citing works

CTLA-4-Mediated Inhibition of Early Events of T Cell Proliferation

Brunner-Weinzierl, M. C., Chambers, C. A., Chan, F. K.-M., Hanke, J., Winoto, A., & Allison, J. P. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.10.5813 · Cited by 419 · see citing works

Epidemiology of invasive cutaneous melanoma

MacKie, R. M., Hauschild, A., & Eggermont, A. M. M. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp252 · Cited by 405 · see citing works

Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma

Castle, J. C., Löewer, M., Boegel, S., de Graaf, J., Bender, C., Tadmor, A. D., Boisguérin, V., Bukur, T., Sorn, P., Paret, C., et al. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-190 · Cited by 386 · see citing works

Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma

Kwong, L. N., Costello, J. C., Liu, H., Jiang, S., Helms, T. L., Langsdorf, A. E., Jakubosky, D., Genovese, G., Muller, F. L., Jeong, J. H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2941 · Cited by 358 · see citing works

Tailoring to RB: tumour suppressor status and therapeutic response

Knudsen, E. S., & Knudsen, K. E. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2401 · Cited by 345 · see citing works

Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

Ascierto, P. A., Ferrucci, P. F., Fisher, R. A., Vecchio, M. D., Atkinson, V. G., Schmidt, H., Schachter, J., Queirolo, P., Long, G. V., Giacomo, A. M. D., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0448-9 · Cited by 326 · see citing works

Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials

Long, G. V., Grob, J., Nathan, P., Ribas, A., Robert, C., Schadendorf, D., Lane, S. R., Mak, C., Legenne, P., Flaherty, K. T., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30578-2 · Cited by 316 · see citing works

A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors

Verma, V., Sprave, T., Haque, W. M., Simone, C. B., Chang, J. Y., Welsh, J. W., & Thomas, C. R. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0442-7 · Cited by 314 · see citing works

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomas

Smalley, K. S. M., Lioni, M., Palma, M. D., Xiao, M., Desai, B. M., Egyházi, S., Hansson, J., Wu, H., King, A. J., Belle, P. A. V., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0431 · Cited by 310 · see citing works

The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma

Sheppard, K. E., & McArthur, G. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0259 · Cited by 266 · see citing works

Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression

Jin, X., Ding, D., Yan, Y., Li, H., Wang, B., Ma, L., Ye, Z., Ma, T., Wu, Q., Rodrigues, D. N., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.10.034 · Cited by 261 · see citing works

Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)

Schwartz, G. K., LoRusso, P. M., Dickson, M. A., Randolph, S. S., Shaik, M. N., Wilner, K. D., Courtney, R., & O'Dwyer, P. J. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.177 · Cited by 260 · see citing works

Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade

Cooper, Z. A., Juneja, V. R., Sage, P. T., Frederick, D. T., Piris, A., Mitra, D., Lo, J. A., Hodi, F. S., Freeman, G. J., Bosenberg, M., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0215 · Cited by 258 · see citing works

Basis of CTLA-4 function in regulatory and conventional CD4+ T cells

Tai, X., Laethem, F. V., Pobezinsky, L. A., Guinter, T. I., Sharrow, S. O., Adams, A., Granger, L. G., Kruhlak, M. J., Lindsten, T., Thompson, C. B., et al. (2012) · Blood · doi:10.1182/blood-2011-11-388918 · Cited by 251 · see citing works

BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell Immunotherapy

Koya, R. C., Mok, S., Otte, N. J., Blacketor, K. J., Comin-Anduix, B., Tumeh, P. C., Minasyan, A., Graham, N. A., Graeber, T. G., Chodon, T., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2837 · Cited by 234 · see citing works

Trends in clinical development for PD-1/PD-L1 inhibitors

Yu, J. X., Hodge, J. P., Oliva, C., Neftelinov, S. T., Hubbard-Lucey, V. M., & Tang, J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/d41573-019-00182-w · Cited by 229 · see citing works

Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors

Ackerman, A., Klein, O., McDermott, D. F., Wang, W., Ibrahim, N., Lawrence, D. P., Gunturi, A., Flaherty, K. T., Hodi, F. S., Kefford, R. F., et al. (2014) · Cancer · doi:10.1002/cncr.28620 · Cited by 220 · see citing works

Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti–CTLA-4 antibody

Ha, D., Tanaka, A., Kibayashi, T., Tanemura, A., Sugiyama, D., Wing, J. B., Lim, E. L., Teng, K. W. W., Adeegbe, D., Newell, E. W., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1812186116 · Cited by 205 · see citing works

Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages.

Yang, Y., Zou, J.-P., Mu, J., Wijesuriya, R., Ono, S., Walunas, T. L., Bluestone, J. A., Fujiwara, H., & Hamaoka, T. (1997) · PubMed · Cited by 197 · see citing works

Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer

Teo, Z. L., Versaci, S., Dushyanthen, S., Caramia, F., Savas, P., Mintoff, C. P., Zethoven, M., Virassamy, B., Luen, S. J., McArthur, G. A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2210 · Cited by 196 · see citing works

Diverse Mechanisms of BRAF Inhibitor Resistance in Melanoma Identified in Clinical and Preclinical Studies

Luebker, S. A., & Koepsell, S. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00268 · Cited by 194 · see citing works

Targeting the ERK Signaling Pathway in Melanoma

Savoia, P., Fava, P., Casoni, F., & Cremona, O. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061483 · Cited by 188 · see citing works

CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice

Tivol, E. A., Boyd, S. D., Mckeon, S., Borriello, F., Nickerson, P. W., Strom, T. B., & Sharpe, A. H. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.11.5091 · Cited by 185 · see citing works

Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma

Sensi, M., Nicolini, G., Petti, C., Bersani, I., Lozupone, F., Molla, A., Vegetti, C., Nonaka, D., Mortarini, R., Parmiani, G., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209379 · Cited by 183 · see citing works

Development of encorafenib for BRAF-mutated advanced melanoma

Koelblinger, P., Olaf, T., & Dummer, R. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000426 · Cited by 180 · see citing works

Inhibitors of the PD-1 Pathway in Tumor Therapy

LaFleur, M. W., Muroyama, Y., Drake, C. G., & Sharpe, A. H. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701044 · Cited by 173 · see citing works

Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.

Ascierto, P., Dummer, R., Gogas, H., Flaherty, K., Arance, A., Mandalà, M., Liszkay, G., Garbe, C., Schadendorf, D., Krajsová, I., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2019.11.016 · Cited by 160 · see citing works

Induction of therapeutic senescence in vemurafenib-resistant melanoma by extended inhibition of CDK4/6

Yoshida, A., Lee, E. K., & Diehl, J. A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2931 · Cited by 153 · see citing works

Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma

Deken, M. A., Gadiot, J., Jordanova, E. S., Lacroix, R., van Gool, M. M. J., Kroon, P., Pineda, C., Foppen, M. H. G., Scolyer, R. A., Song, J., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1238557 · Cited by 153 · see citing works

Opdivo (Nivolumab): Second PD-1 Inhibitor Receives FDA Approval for Unresectable or Metastatic Melanoma.

Raedler, L. A. (2015) · PubMed · Cited by 151 · see citing works

Vemurafenib enhances MHC induction inBRAFV600Ehomozygous melanoma cells

Sapkota, B., Hill, C. E., & Pollack, B. P. (2013) · OncoImmunology · doi:10.4161/onci.22890 · Cited by 146 · see citing works

Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab

Minor, D. R., Puzanov, I. J., Callahan, M. K., Hug, B. A., & Hoos, A. (2015) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12383 · Cited by 144 · see citing works

Inactivation of thePTEN/MMAC1/TEP1 gene in human lung cancers

Kohno, T., Takahashi, M., Manda, R., & Yokota, J. (1998) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199806)22:2 · Cited by 142 · see citing works

MEK Inhibition, Alone or in Combination with BRAF Inhibition, Affects Multiple Functions of Isolated Normal Human Lymphocytes and Dendritic Cells

Vella, L. J., Pasam, A., Dimopoulos, N., Andrews, M., Knights, A., Puaux, A.-L., Louahed, J., Chen, W., Woods, K., & Cebon, J. S. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0181 · Cited by 139 · see citing works

Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials

Pelster, M. S., & Amaria, R. N. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919830826 · Cited by 137 · see citing works

MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation

Bommareddy, P. K., Aspromonte, S. M., Zloza, A., Rabkin, S. D., & Kaufman, H. L. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aau0417 · Cited by 133 · see citing works

The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation

Yadav, V., Burke, T. F., Huber, L., Van Horn, R. D., Zhang, Y., Buchanan, S. G., Chan, E. M., Starling, J. J., Beckmann, R. P., & Peng, S.-B. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0257 · Cited by 132 · see citing works

BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth

Wang, T., Xiao, M., Ge, Y., Krepler, C., Belser, E., López-Coral, A., Xu, X., Zhang, G., Azuma, R., Liu, Q., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1554 · Cited by 130 · see citing works

Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma

Yu, C., Liu, X., Yang, J., Zhang, M., Jin, H., Ma, X., & Shi, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00990 · Cited by 126 · see citing works

Efficacy of the combination of MEK and CDK4/6 inhibitors<i>in vitro</i>and<i>in vivo</i>in KRAS mutant colorectal cancer models

Lee, M. S., Helms, T. L., Feng, N., Gay, J., Chang, Q. E., Tian, F., Wu, J. Y., Toniatti, C., Heffernan, T. P., Powis, G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9153 · Cited by 123 · see citing works

Melanocytes are deficient in repair of oxidative DNA damage and UV-induced photoproducts

Wang, H.-T., Choi, B., & Tang, M.-S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005244107 · Cited by 119 · see citing works

Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF Inhibitor

Callahan, M. K., Masters, G. R., Pratilas, C. A., Ariyan, C. E., Katz, J. B., Kitano, S., Russell, V., Gordon, R. A., Vyas, S., Yuan, J. D., et al. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0160 · Cited by 116 · see citing works

Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma

Ferrari de Andrade, L., Ngiow, S. F., Stannard, K., Rusakiewicz, S., Kalimutho, M., Khanna, K. K., Tey, S.-K., Takeda, K., Zitvogel, L., Martinet, L., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1339 · Cited by 105 · see citing works

Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study

Gogas, H., Dréno, B., Larkin, J., Demidov, L., Stroyakovskiy, D., Eroglu, Z., Francesco Ferrucci, P., Pigozzo, J., Rutkowski, P., Mackiewicz, J., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.12.004 · Cited by 102 · see citing works

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

Ozaki, A., Tanimoto, T., & Saji, S. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1510345 · Cited by 102 · see citing works

Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma

Moreno, B. H., Mok, S., Comin-Anduix, B., Hu‐Lieskovan, S., & Ribas, A. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1052212 · Cited by 101 · see citing works

Effects of BRAF Mutations and BRAF Inhibition on Immune Responses to Melanoma

Ilieva, K. M., Corrêa, I., Josephs, D. H., Karagiannis, P., Egbuniwe, I. U., Cafferkey, M., Spicer, J. F., Harries, M., Nestle, F. O., Lacy, K. E., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0290 · Cited by 88 · see citing works

Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma

Dummer, R., Ascierto, P. A., Nathan, P., Robert, C., & Schadendorf, D. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.4401 · Cited by 80 · see citing works

In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2–CDK4/6 Targeting and mTOR–S6 Resistance Mechanisms

Teh, J. L. F., Cheng, P. F., Purwin, T. J., Nikbakht, N., Patel, P. S., Chervoneva, I., Ertel, A., Fortina, P. M., Kleiber, I., HooKim, K., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0699 · Cited by 75 · see citing works

Overall survival in patients with metastatic melanoma

Song, X., Zhao, Z., Barber, B., Farr, A. M., Ivanov, B., & Novich, M. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1021904 · Cited by 71 · see citing works

Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance

Martin, C. A., Cullinane, C. M., Kirby, L., AbuHammad, S., Lelliott, E. J., Waldeck, K., Young, R. J., Brajanovski, N., Cameron, D. P., Walker, R., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.31220 · Cited by 68 · see citing works

LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial

Nathan, P., Dummer, R., Long, G. V., Ascierto, P. A., Tawbi, H., Robert, C., Rutkowski, P. L., Леонов, О. В., Dutriaux, C., Mandalà, M., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2273 · Cited by 67 · see citing works

Genomic analysis and 3-y efficacy and safety update of COMBI-d: A phase 3 study of dabrafenib (D) + trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma.

Flaherty, K. T., Davies, M. A., Grob, J., Long, G. V., Nathan, P., Ribas, A., Robert, C., Schadendorf, D., Frederick, D. T., Hammond, M. R., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.9502 · Cited by 66 · see citing works

Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma

Amin, A., Lawson, D. H., Salama, A. K. S., Koon, H. B., Guthrie, T. H., Thomas, S. S., O'Day, S. J., Shaheen, M. F., Zhang, B., Francis, S., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0148-7 · Cited by 61 · see citing works

ERK Inhibition: A New Front in the War against MAPK Pathway–Driven Cancers?

Smalley, I., & Smalley, K. S. M. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1355 · Cited by 60 · see citing works

Up-to-date survival estimates and historical trends of cutaneous malignant melanoma in the south-east of The Netherlands

de Vries, E., Houterman, S., Janssen-Heijnen, M. L. G., Nijsten, T. E. C., van de Schans, S. A. M., Eggermont, A. M. M., & Coebergh, J. W. W. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm087 · Cited by 57 · see citing works

Cell Cycle Control by Oncogenes and Tumor Suppressors: Driving the Transformation of Normal Cells into Cancerous Cells

Chow, A. Y. M. (2010) · Cited by 57 · see citing works

Combination of RAF and MEK Inhibition for the Treatment of BRAF-Mutated Melanoma: Feedback Is Not Encouraged

Chapman, P. B., Solit, D. B., & Rosen, N. X. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.017 · Cited by 52 · see citing works

Anti–PD-1 Therapy in Melanoma

Moreno, B. H., Parisi, G., Robert, L., & Ribas, A. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.02.008 · Cited by 49 · see citing works

Mitogen-activated protein kinase cascade and transcription factors: the opposite role of MKK3/6-p38K and MKK1-MAPK

Terada, Y. (1999) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/14.suppl_1.45 · Cited by 48 · see citing works

Exploring Molecular Mechanisms of Paradoxical Activation in the BRAF Kinase Dimers: Atomistic Simulations of Conformational Dynamics and Modeling of Allosteric Communication Networks and Signaling Pathways

Tse, A., & Verkhivker, G. M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166583 · Cited by 48 · see citing works

Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF -Mutant Melanoma

Ribas, A., DAUD, A. I., Pavlick, A. C., Gonzalez, R. C., Lewis, K. D., Hamid, O., Gajewski, T. F., Puzanov, I. J., Wongchenko, M. J., Rooney, I. A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4180 · Cited by 45 · see citing works

Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma

Simeone, E., Grimaldi, A. M., Festino, L., Giannarelli, D., Vanella, V., Palla, M., Curvietto, M., Esposito, A., Palmieri, G., Mozzillo, N., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1283462 · Cited by 40 · see citing works

Mechanisms of Resistance to RAF Inhibition in Melanomas Harboring a BRAF Mutation

Chapman, P. B. (2013) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2013.33.e80 · Cited by 38 · see citing works

Dabrafenib: a new opportunity for the treatment of BRAF V600-positive melanoma

Argenziano, G., Banzi, C., Blasio, S. D., Lallas, A., Longo, C., Moscarella, E., & Alfano, R. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s75104 · Cited by 36 · see citing works

KEYNOTE-022 update: phase 1 study of first-line pembrolizumab (pembro) plus dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma

Ribas, A., Hodi, F. S., Lawrence, D. P., Atkinson, V. G., Agarwal, S., Carlino, M. S., Fisher, R. A., Long, G. V., Miller, W. H., Huang, Y., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx377.003 · Cited by 36 · see citing works

Preliminary findings from part 1 of COMBI-i: A phase III study of anti–PD-1 antibody PDR001 combined with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600-mutant melanoma.

Dummer, R., Arance, A. M., Hansson, J., Larkin, J., Long, G. V., Gasal, E., Kaper, M., Upalawanna, A., Mookerjee, B., & Atkinson, V. G. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.5_suppl.189 · Cited by 34 · see citing works

BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells

Atay, Ç., Kwak, T., Lavilla-Alonso, S., Donthireddy, L., Richards, A. D., Moberg, V. E., Pilon‐Thomas, S., Schell, M. J., Messina, J. L., Rebecca, V. W., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2725 · Cited by 34 · see citing works

A phase Ib/II dose-escalation study evaluating triple combination therapy with a BRAF (encorafenib), MEK (binimetinib), and CDK 4/6 (ribociclib) inhibitor in patients (Pts) with BRAF V600-mutant solid tumors and melanoma.

Ascierto, P. A., Bechter, O. E., Wolter, P., Lebbé, C., Élez, E., Miller, W. H., Long, G. V., Omlin, A. G., Siena, S., Calvo, E., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.9518 · Cited by 32 · see citing works

A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma

Mooradian, M. J., Reuben, A., Prieto, P. A., Hazar-Rethinam, M. H., Frederick, D. T., Nadres, B., Piris, A., Juneja, V. R., Cooper, Z. A., Sharpe, A. H., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1423172 · Cited by 27 · see citing works

The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non–Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review

Chai, Q., Du, J., Zhu, J., & Wu, B. Y. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01260 · Cited by 25 · see citing works

Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma

Lelliott, E. J., Mangiola, S., Ramsbottom, K. M., Zethoven, M., Lim, L. R. J., Lau, P. K. H., Oliver, A. J., Martelotto, L. G., Kirby, L., Martin, C., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0401 · Cited by 24 · see citing works

Vemurafenib and ipilimumab: A promising combination? Results of a case series

Hassel, J. C., Lee, S. B., Meiß, F., Meier, F. E., Dimitrakopoulou‐Strauss, A., Jäger, D., & Enk, A. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1101207 · Cited by 22 · see citing works

MEK/CDK4,6 co-targeting is effective in a subset of NRAS, BRAF and ‘wild type’ melanomas

Posch, C., Sanlorenzo, M., Ma, J., Kim, S. T., Zekhtser, M., & Ortiz-Urda, S. (2018) · OncoTarget · doi:10.18632/oncotarget.26204 · Cited by 18 · see citing works

Role of Cdk4 in lymphocyte function and allergen response

Chow, Y. H., Zhu, X. D., Liu, L., Schwartz, B. R., Huang, X. Z., Harlan, J. M., & Schnapp, L. M. (2010) · Cell Cycle · doi:10.4161/cc.9.24.14209 · Cited by 15 · see citing works

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445 · see citing works

Managing Metastatic Melanoma in 2022: A Clinical Review

Switzer, B., Puzanov, I., Skitzki, J. J., Hamad, L., & Ernstoff, M. S. (2022) · JCO Oncology Practice · doi:10.1200/op.21.00686 · Cited by 208 · see citing works

Advancing Cancer Treatment: A Review of Immune Checkpoint Inhibitors and Combination Strategies

Neil, V. M., & Lee, S. W. (2025) · Cancers · doi:10.3390/cancers17091408 · Cited by 61 · see citing works

Sepsis in patients who are immunocompromised: diagnostic challenges and future therapies

Deinhardt‐Emmer, S., Chousterman, B. G., Schefold, J. C., Flohé, S. B., Skirecki, T., Kox, M., Winkler, M. S., Cossarizza, A., Wiersinga, W. J., van der Poll, T., et al. (2025) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(25)00124-9 · Cited by 59 · see citing works

BRAF mutation status and its prognostic significance in 79 canine urothelial carcinomas: A retrospective study (2006–2019)

Gedon, J., Kehl, A., Aupperle‐Lellbach, H., von Bomhard, W., & Schmidt, J. M. (2021) · Veterinary and Comparative Oncology · doi:10.1111/vco.12790 · Cited by 43 · see citing works

MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas

Stopfer, L. E., Rettko, N. J., Leddy, O. K., Mesfin, J. M., Brown, E. N., Winski, S. L., Bryson, B. D., Wells, J. A., & White, F. M. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2208900119 · Cited by 37 · see citing works

Targeting the Epigenome in Malignant Melanoma: Facts, Challenges and Therapeutic Promises

Anestopoulos, I., Kyriakou, S., Tragkola, V., Paraskevaidis, I., Tzika, E., Mitsiogianni, M., Deligiorgi, M. V., Petrakis, G., Trafalis, D. T., Botaitis, S., et al. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108301 · Cited by 35 · see citing works

Advances in Materials Science for Precision Melanoma Therapy: Nanotechnology-Enhanced Drug Delivery Systems

Moni, S. S., Moshi, J. M., Matou‐Nasri, S., Alotaibi, S., Hawsawi, Y. M., Elmobark, M. E., Hakami, A., Jeraiby, M., Sulayli, A. A., & Moafa, H. N. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17030296 · Cited by 35 · see citing works

The future of targeted kinase inhibitors in melanoma

Caksa, S., Baqai, U., & Aplin, A. E. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108200 · Cited by 33 · see citing works

Targeted deletion of CD244 on monocytes promotes differentiation into anti-tumorigenic macrophages and potentiates PD-L1 blockade in melanoma

Kim, J., Kim, T., Chae, S., Ha, H., Park, Y., Park, S. H., Yoon, C. J., Lim, S. A., Lee, H., Kim, J., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01936-w · Cited by 27 · see citing works

Deciphering the Immunomodulatory Role of Cyclin-Dependent Kinase 4/6 Inhibitors in the Tumor Microenvironment

Pandey, P., Khan, F., Upadhyay, T. K., & Sharangi, A. B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032236 · Cited by 23 · see citing works

Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy: The more, the better?

Haist, M., Stege, H. M., Kuske, M., Bauer, J., Klumpp, A., Grabbe, S., & Bros, M. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10097-z · Cited by 23 · see citing works

Emerging biomarkers in melanoma: Bridging molecular discovery and precision oncology

Xu, S., Huang, Z., Li, Y., Lu, L., & Ma, W. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218359 · Cited by 19 · see citing works

Targeting Melanin in Melanoma with Radionuclide Therapy

Allen, K. J. H., Malo, M. E., Jiao, R., & Dadachova, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179520 · Cited by 18 · see citing works

Hernandezine Regulates Proliferation and Autophagy-Induced Apoptosis in Melanoma Cells

Wang, X., Li, X., Xia, Y., Wang, D., Li, X., Liu, L., Zheng, Q., Li, D., & Jiang, Q. (2022) · Journal of Natural Products · doi:10.1021/acs.jnatprod.2c00098 · Cited by 17 · see citing works

Gut Microbiota and Therapy in Metastatic Melanoma: Focus on MAPK Pathway Inhibition

Guardamagna, M., Berciano‐Guerrero, M., González, B. V., Pérez-Ruiz, E., Oliver, J., Lavado-Valenzuela, R., Rueda‐Domínguez, A., Barragán, I., & Queipo‐Ortuño, M. I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911990 · Cited by 17 · see citing works

Targeting protein kinases benefits cancer immunotherapy

Zhang, Z., Bu, L., Luo, J., & Guo, J. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188738 · Cited by 17 · see citing works

Blocking Nitrosylation Induces Immunogenic Cell Death by Sensitizing NRAS -Mutant Melanoma to MEK Inhibitors

Srivastava, J., Yadav, V., Jimenez, R. V., Phadatare, P. R., Inamdar, N. A., Young, M. M., Bacchiocchi, A., Halaban, R., Fang, B., Pulido, Á. D. M., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-0693 · Cited by 15 · see citing works

A Theranostic Approach to Imaging and Treating Melanoma with 203Pb/212Pb-Labeled Antibody Targeting Melanin

Jiao, R., Allen, K. J. H., Malo, M. E., Yilmaz, O., Wilson, J. S., Nelson, B. J. B., Wuest, F. R., & Dadachova, E. (2023) · Cancers · doi:10.3390/cancers15153856 · Cited by 15 · see citing works

Targeting cyclin-dependent kinase 4/6 as a therapeutic approach for mucosal melanoma

Shi, C.-J., Xu, S.-M., Han, Y., Zhou, R., & Zhang, Z.-Y. (2021) · Melanoma Research · doi:10.1097/cmr.0000000000000777 · Cited by 13 · see citing works

BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes

Lee, J., Ahmed, T., Maurichi, A., Guardo, L. D., Stagno, A. M., Warburton, L., Taylor, A. M., Livingstone, E., Rehman, S., Khattak, A., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.11.009 · Cited by 13 · see citing works

Cancer Metastasis: Therapeutic Challenges and Opportunities

Garemilla, S. S. S., Kadambala, M. C., Gampa, S. C., Chinthala, S., & Garimella, S. V. (2025) · Medical Oncology · doi:10.1007/s12032-025-03072-x · Cited by 13 · see citing works

A Mathematical Model for the Treatment of Melanoma with the BRAF/MEK Inhibitor and Anti-PD-1

Nave, O., & Sigron, M. (2022) · Applied Sciences · doi:10.3390/app122312474 · Cited by 11 · see citing works

Towards Better Pharmaceutical Provision in Europe—Who Decides the Future?

Horgan, D., Španić, T., Apostolidis, K., Curigliano, G., Chorostowska‐Wynimko, J., Dauben, H., Lal, J. A., Dziadziuszko, R., Mayer‐Nicolai, C., Kozaric, M., et al. (2022) · Healthcare · doi:10.3390/healthcare10081594 · Cited by 10 · see citing works

CDK4/6 Inhibition Induces CD8 + T Cell Antitumor Immunity via MIF‐Induced Functional Orchestration of Tumor‐Associated Macrophages

He, L., Peng, Y., Leong, L., Zhou, J., Tang, D., Wang, W., Wu, X., Lei, J. H., Ye, Y., Feng, Y., et al. (2025) · Advanced Science · doi:10.1002/advs.202511330 · Cited by 10 · see citing works

A patent review of small molecule CDK4/6 inhibitors in the treatment of cancer: 2020–present

Huang, X., Xu, S., Duan, L., Xu, S., & Zhu, W. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2379926 · Cited by 9 · see citing works

Antitumor effects of immunotherapy combined with BRAF and MEK inhibitors in BRAF V600E metastatic colorectal cancer

Tak, E., An, H., Lee, A. S., Han, K., Choi, J., Kim, H., Hong, Y. S., Kim, S., Choi, E. K., Kim, J. E., et al. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04005-3 · Cited by 9 · see citing works

Histopathologic and Molecular Insights Following the Management of Ameloblastomas via Targeted Therapies – Pathological and Clinical Perspectives

Hirschhorn, A., Grynberg, S., Campino, G. A., Dobriyan, A., Patel, V., Greenberg, G., Yacobi, R., Barshack, I., Yahalom, R., Toren, A., et al. (2024) · Head and Neck Pathology · doi:10.1007/s12105-024-01734-2 · Cited by 7 · see citing works

In Situ Cancer Vaccines: Redefining Immune Activation in the Tumor Microenvironment

Giram, P. S., Rahman, K. M. M., Aqel, O., & You, Y. (2025) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.5c00121 · Cited by 7 · see citing works

Recruiting Immunity for the Fight against Colorectal Cancer: Current Status and Challenges

Al-Hujaily, E. M., Al-Sowayan, B. S., Alyousef, Z., Uddin, S., & Alammari, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213696 · Cited by 6 · see citing works

New emerging treatment options for metastatic melanoma: a systematic review and meta-analysis of skin cancer therapies

Jarab, A. S., Al-Qerem, W. A., Khdour, L. M., Mimi, Y., & Khdour, M. R. (2024) · Archives of Dermatological Research · doi:10.1007/s00403-024-03467-2 · Cited by 6 · see citing works

Circular RNA MYLK as a prognostic biomarker in patients with cancers: A systematic review and meta‐analysis

Foroumadi, R., Rashedi, S., Asgarian, S., Mardani, M., Keykhaei, M., Farrokhpour, H., Javanshir, S., Sarallah, R., & Rezaei, N. (2022) · Cancer Reports · doi:10.1002/cnr2.1653 · Cited by 6 · see citing works

Addressing the unmet needs of patients with BRAF-mutated melanoma in Latin America: Expert perspective

Salman, P., de Melo, A. C., Rico-Restrepo, M., Rodriguez, J., Russi, A., Schmerling, R. A., Zambrano, A. R., & Cinat, G. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1032300 · Cited by 6 · see citing works

A Consolidated Review of Contemporary Targeted and Immunotherapeutic Options for Melanoma

Champion, P. J., Bluestein, J. R., Quinn, A. E., Bell, S. D., Kiley, J. H., Wakefield, M. R., & Fang, Y. (2025) · Biomedicines · doi:10.3390/biomedicines13061388 · Cited by 6 · see citing works

Advances in Cutaneous Melanoma Therapy: The Emerging Role of CDK4/6 Inhibitors

Kim, U., McCormick, T. S., Mangla, A., Cooper, K. D., Schwartz, G. K., & Yoshida, A. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107955 · Cited by 5 · see citing works

Pathway-Specific Therapeutic Modulation of Melanoma: Small-Molecule Inhibition of BRAF–MEK and KIT Signaling in Contemporary Precision Oncology with a Special Focus on Vemurafenib, Trametinib, and Imatinib

Kawczak, P., & Bączek, T. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14227906 · Cited by 5 · see citing works

Tretinoin synergistically enhances the antitumor effect of combined BRAF, MEK, and EGFR inhibition in BRAFV600E colorectal cancer

Yoshida, Y., Takahashi, M., Taniguchi, S. H., Numakura, R., Komine, K., & Ishioka, C. (2024) · Cancer Science · doi:10.1111/cas.16280 · Cited by 4 · see citing works

A Case of Pulmonary Sarcoidosis during First-Line Targeted Therapy with Dabrafenib Plus Trametinib in BRAF V600E-Mutated Metastatic Melanoma

Tronconi, M. C., Marinello, A., Solferino, A., Grimaudo, M. S., Ciccarelli, M., Manara, S. A. A. M., Cozzaglio, L., Mancini, L. L., Borroni, R. G., & Santoro, A. (2022) · Case Reports in Oncology · doi:10.1159/000524185 · Cited by 5 · see citing works

High expression of NOLC1 as an independent prognostic factor for survival in patients with colorectal cancer

Sun, Z., Zhang, Q., Lv, J., Sun, Y., Feng, Z., Zhang, M., Zhang, F., Xia, C., Gao, Y., Zhang, Z., et al. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05297-7 · Cited by 5 · see citing works

Changes in the Transcriptome and Chromatin Landscape in BRAFi-Resistant Melanoma Cells

Reddi, K. K., Guruvaiah, P., Edwards, Y. J. K., & Gupta, R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.937831 · Cited by 5 · see citing works

Multi-tyrosine kinase inhibitors: exploring immunomodulatory effects on various immune cell types in cancer

Keshavarz, F., Soltanshahi, M., Ayadilord, M., Mortazavi, F. S., Shabani, M., & Jalali, S. A. (2026) · Cancer Cell International · doi:10.1186/s12935-025-04141-x · Cited by 4 · see citing works

Anticancer Effects of Ascorbic Acid: Not All Sides Fit All

Arunsi, U. O., Olugbami, J. O., & Oyelere, A. K. (2025) · Cancers · doi:10.3390/cancers17172877 · Cited by 4 · see citing works

Case Report: Balancing immune responses – multiple sclerosis disease exacerbation under BRAF/MEK treatment for malignant melanoma

Pape, K., Protopapa, M., Schraad, M., Steffen, F., Zipp, F., & Bittner, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1303141 · Cited by 4 · see citing works

New Standards in the Treatment of Advanced Metastatic Melanoma: Immunotherapy and BRAF-Targeted Therapies as Emerging Paradigms

Kreidieh, F., & Wong, M. K. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128341628250519093548 · Cited by 4 · see citing works

Simultaneous targeting of KRAS and CDK4 synergistically induces durable growth arrest in pancreatic cancer cells

Paulsohn, M.-B., Frahnert, K. H., Schlösser, D., Oschwald, J., Kopp, W., Fang, X., Schneider, C., Contreras, C. T., Danieli‐Mackay, A., Ludewig, F., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08362-w · Cited by 3 · see citing works

Potential role of cyclin-dependent kinase 4/6 inhibitors in the treatment of mucosal melanoma

Shi, C., Ju, H., Wu, Y., Ma, X., Zhang, Z., & Ren, G. (2024) · Holistic Integrative Oncology · doi:10.1007/s44178-024-00090-z · Cited by 2 · see citing works

Antitumorigenic Effect of Combination Treatment with BRAF Inhibitor and Cisplatin in Colorectal Cancer In Vitro and In Vivo

Koumaki, K., Skarmalioraki, S., Kosmidou, V., Krikoni, L., Goulielmaki, M., Zoumpourlis, V. C., Pintzas, A., & Souliotis, V. L. (2024) · Advanced Therapeutics · doi:10.1002/adtp.202400250 · Cited by 2 · see citing works

Characterization of m6A methylation modifications in gastric cancer

Yin, W., Huo, Z., Zuo, J., Wang, H., Chen, B., & Zhou, L. (2023) · Aging · doi:10.18632/aging.205341 · Cited by 1 · see citing works

CDK4/6-targeted therapy: From clinical inhibitors to emerging strategies to overcome resistance

Sha, W., Feng, D., Yan, Z., Chen, Z., & Lu, Y. (2026) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2026.118736 · Cited by 1 · see citing works

Phytotherapeutic potential of Campomanesia xanthocarpa (Mart.) O. Berg: antitumor effects in vitro and in silico, with emphasis on SK-MEL-28 melanoma cells—a study on leaf and fruit infusions

da Silva, V. R. F., da Silva, G. B., Manica, D., Deolindo, C. T. P., Bagatini, M. D., & Kempka, A. P. (2024) · In Silico Pharmacology · doi:10.1007/s40203-024-00286-1 · Cited by 1 · see citing works

Relation between dabrafenib plus trametinib-induced pyrexia and age in BRAF V600-mutated metastatic melanoma patients: A post hoc analysis of the real-world ELDERLYMEL study

González‐Barrallo, I., Rubio, V. E. C., Medina, J., España, S., Mujika, K., Majem, M., Aguado, C., Suárez, M. Á. C., Palacio, I., Osterloh, L., et al. (2025) · Melanoma Research · doi:10.1097/cmr.0000000000001020 · Cited by 1 · see citing works

Metabolism-oriented compound screen in physiological culture conditions identifies a NAMPT inhibitor highly effective against drug-naïve and -resistant melanoma cellsPreprint

Preis, J. R., Rolvering, C., Kirchmeyer, M., Kreis, S., Behrmann, I., & Haan, C. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.23.619802 · Cited by 2 · see citing works

Simultaneous Targeting of KRAS and CDK4 Synergistically Suppresses Pancreatic Cancer CellsPreprint

Paulsohn, M.-B., Frahnert, K. H., Fang, X., Schneider, C., Contreras, C. T., Schneider, G., Heßmann, E., & Dobbelstein, M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.11.632518 · Cited by 1 · see citing works

Modern Views and Analysis of Promising Approaches to the Treatment of Melanoma

Сафроненко, А. В., Куделина, О. М., Ганцгорн, Е. В., Buraeva, M. K.-B., Buraeva, M. K.-B., Miteneva, A. A., Shvelidze, L. R., Kalmykova, D. A., Ilyina, A. A., & Lachinov, V. Z. (2023) · Journal Biomed · doi:10.33647/2074-5982-19-3-47-52

Unveiling the Research Landscape and Emerging Trends in Cell Cycle for Cancer Immunotherapy: A Bibliometric Analysis (1990-2022)

Feng, C., Li, Y., Zang, M., Jin-si-han, E.-E.-M.-B.-K., He, M., & Lu, Z. (2023) · Medical Science Monitor · doi:10.12659/msm.940556

Metastatic melanoma of the oral cavity showing prompt regression with the use of BRAF / MEK inhibitors

Oya, K., Ishizuki, S., Yasunaga, S., Fujisawa, Y., & Nomura, T. (2023) · The Journal of Dermatology · doi:10.1111/1346-8138.17019

The use of BRAF-inhibitors as monotherapy and in combination with cytosine arabinoside and 2-chloro-2’deoxyadenosine in pediatric patients with different forms of Langerhans cell histiocytosis

Бурцев, Е. А., Evseev, D. A., Gaziev, I. R., Львовна, Л. Л., Skоbееv, D. А., Osipova, D. S., Бронин, Г. О., & Maschan, M. A. (2024) · Russian Journal of Pediatric Hematology and Oncology · doi:10.21682/2311-1267-2023-10-4-13-24

BRAF mutations in ovarian cancer: immune microenvironment and therapeutic advances

Wang, Y., & Du, X. (2025) · Journal of Molecular Histology · doi:10.1007/s10735-025-10597-y

The role of signaling pathways in melanocyte malignant transformation and components of signaling cascades as targets for melanoma therapy

Vorobev, K. P., Stepovaya, E. A., Nosareva, O. L., Спирина, Л. В., & Nagaitsev, V. М. (2025) · Kazan medical journal · doi:10.17816/kmj685457

mTORC1/2 inhibition induces tumor regression in CDK4/6 inhibitor-insensitive acral melanoma

Bravo, J., Jagirdar, K., Begum, S., Yu, K., Wei, M., Roberson, B., Portuallo, M. E., An, L., Hallis, S. P., Smart, V. A., et al. (2025) · Cancer Gene Therapy · doi:10.1038/s41417-025-00987-5

Additional file 2 of Targeted deletion of CD244 on monocytes promotes differentiation into anti-tumorigenic macrophages and potentiates PD-L1 blockade in melanoma

Kim, J., Kim, T.-J., Chae, S., Ha, H., Park, Y., Park, S., Yoon, C. J., Lim, S. A., Lee, H., Kim, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25322972

Additional file 1 of Targeted deletion of CD244 on monocytes promotes differentiation into anti-tumorigenic macrophages and potentiates PD-L1 blockade in melanoma

Kim, J., Kim, T.-J., Chae, S., Ha, H., Park, Y., Park, S. H., Yoon, C. J., Lim, S. A., Lee, H., Kim, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25322837

Additional file 4 of Targeted deletion of CD244 on monocytes promotes differentiation into anti-tumorigenic macrophages and potentiates PD-L1 blockade in melanoma

Kim, J., Kim, T.-J., Chae, S., Ha, H., Park, Y., Park, S., Yoon, C. J., Lim, S. A., Lee, H., Kim, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26687040

Additional file 3 of Targeted deletion of CD244 on monocytes promotes differentiation into anti-tumorigenic macrophages and potentiates PD-L1 blockade in melanoma

Kim, J., Kim, T.-J., Chae, S., Ha, H., Park, Y., Park, S. H., Yoon, C. J., Lim, S. A., Lee, H., Kim, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26687037

Additional file 5 of Targeted deletion of CD244 on monocytes promotes differentiation into anti-tumorigenic macrophages and potentiates PD-L1 blockade in melanoma

Kim, J., Kim, T.-J., Chae, S., Ha, H., Park, Y., Park, S. H., Yoon, C. J., Lim, S. A., Lee, H., Kim, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26687043

Immunotherapy in Melanoma: A Dynamic Frontier in Cancer Treatment

Ahmed, A., Alahmadi, M. A., Khawaji, Z. Y., Eissa, A., & Alghamdi, S. (2026) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01377-7

Rewiring the Molecular Interplay of CDK4/6 Inhibitors in Lung Cancer: From Cell Cycle Control to Immune Microenvironment Remodeling

Ku, Y., Zheng, Y., Ding, Y., Zhang, P., Wu, X., & Chen, Y. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27167119

NEW IMMUNOTHERAPY STRATEGIES FOR MELANOMA: CHECKPOINT INHIBITORS, COMBINATION THERAPIES AND mRNA VACCINES

Marcysiak, A., Mularczyk, P., Polek, N., Sikorska, M., Łysoniewski, W., Mruzek, T., Kiełbasiewicz, M., Zawadzka, K., & Marcysiak, A. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6418

Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma

Ziogas, D. C., Konstantinou, F., Bouros, S., Theochari, M., & Gogas, H. J. (2021) · American Journal of Clinical Dermatology · doi:10.1007/s40257-021-00593-9 · Cited by 36 · see citing works

Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy

Kuske, M., Westphal, D., Wehner, R., Schmitz, M., Beissert, S., Praetorius, C., & Meier, F. E. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.08.019 · Cited by 127 · see citing works

Triple Combination of Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors in BRAFV600 Melanoma: Current Status and Future Perspectives

Welti, M., Dimitriou, F., Gutzmer, R., & Dummer, R. (2022) · Cancers · doi:10.3390/cancers14225489 · Cited by 29 · see citing works

Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition

Lau, P. K. H., Ascierto, P. A., & McArthur, G. A. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.12.006 · Cited by 23 · see citing works

Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma

Dummer, R., Ascierto, P. A., Nathan, P., Robert, C., & Schadendorf, D. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.4401 · Cited by 80 · see citing works